Patent ID: 9182385
Filing Date: 2015-11-10
Classification: G01N

Abstract:
1. A method of determining a status of a B-cell receptor signaling pathway in a primary chronic lymphoid leukemia (CLL) cell comprising: contacting said CLL cell with a B-cell receptor modulator which is selected from the group consisting of Rituxan, a cross-linker of a B-cell receptor complex, a B-cell co-receptor complex, F(ab)2 IgM, IgG, IgD, polyclonal BCR antibodies, monoclonal BCR antibodies, Fc receptor derived binding elements and/or combinations thereof; determining an activation level of an activatable element in a B-cell receptor signaling pathway in said CLL cell on a single cell basis, said activatable element comprising p-Erk ½; and determining the status of the B-cell receptor signaling pathway in said CLL cell from said activation level of p-Erk ½.